Here are the 10-K annual reports from Apimeds Pharmaceuticals US, Inc. (APUS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow APUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APUS filings page.
Apimeds Pharmaceuticals US, Inc. filed its annual report describing a transformative merger with MindWave Innovations Inc., completed on December 1, 2025. MindWave became a wholly owned subsidiary, and its former stockholders will receive Company common and preferred stock representing 90.9% of Apimeds’ fully diluted equity.
The report centers on Apitox, a bee venom–based biologic being developed for knee osteoarthritis pain and inflammation, with longer-term potential in multiple sclerosis. Extensive Korean Phase I–III data and a 3,194‑patient post‑marketing safety study support further U.S. development, including a new Phase III knee OA trial aimed at a future biologics license application.